The Oncotype DX Breast Recurrence Score? Test
The Oncotype DX Breast Recurrence Score® test provides a genomic-based, comprehensive, individualized risk assessment for early-stage invasive breast cancer in adjuvant and neoadjuvant settings. The test provides valuable information you can use to personalize a treatment plan specifically for each patient’s situation—including risk of distant recurrence, the benefit from chemotherapy and whether your patient can be treated effectively with hormonal therapy alone. 1-6
The Breast Recurrence Score® is proven to predict the likely benefit of chemotherapy 2,3,5,6 as well as the risk of distant recurrence 1,4 for patients who are newly diagnosed with early-stage invasive breast cancer. Eligible patients are diagnosed with early stage, ER+, HER2- breast cancer with either node-negative or node-positive disease. The test uses RT-PCR to measure the expression of 21 genes: 16 cancer-related genes and five reference genes - in a tumor sample after it has been removed by surgery or biopsy.
The results are presented as a quantitative score, on a scale from 0-100. The score reflects individual tumor biology—the higher the score, the higher the risk of distant recurrence and the higher the likelihood of chemotherapy benefit for that patient. 2 The Recurrence Score® result can serve as a reference point for all members of the treatment team and can make discussing treatment options with your patients easier and more efficient.
For further information, please go to https://www.oncotypedxtest.com/
REFERENCES
The Breast Recurrence Score® is proven to predict the likely benefit of chemotherapy 2,3,5,6 as well as the risk of distant recurrence 1,4 for patients who are newly diagnosed with early-stage invasive breast cancer. Eligible patients are diagnosed with early stage, ER+, HER2- breast cancer with either node-negative or node-positive disease. The test uses RT-PCR to measure the expression of 21 genes: 16 cancer-related genes and five reference genes - in a tumor sample after it has been removed by surgery or biopsy.
The results are presented as a quantitative score, on a scale from 0-100. The score reflects individual tumor biology—the higher the score, the higher the risk of distant recurrence and the higher the likelihood of chemotherapy benefit for that patient. 2 The Recurrence Score® result can serve as a reference point for all members of the treatment team and can make discussing treatment options with your patients easier and more efficient.
For further information, please go to https://www.oncotypedxtest.com/
REFERENCES
1. Paik et al. J Clin Oncol. 2006.
2. Albain et al. Lancet Oncol. 2010.
3. Sparano JA et al. N Engl J Med. 2018.
4. Kalinsky. N Engl J Med. 2021.
5. Kalinsky et al. SABCS. 2021 GS2-07.
6. Partridge et al. J Natl Cancer Inst Monogr. 2001.
7. Friese et al. Cancer. 2017.
8. Groenvold. Dan Med Bull. 2010.
9. EBCTCG. Lancet. 2012.
10. Paik et al. N Engl J Med. 2004.
11. Dowsett M et al. J Clin Oncol. 2010.
12. Nitz et al. Breast Cancer Res Treat. 2017.
13. Geyer et al. NPJ Breast Cancer. 2018.
14. Ballman et al. J Clin Oncol. 2015.
15. Sparano et al. N Engl J Med. 2019.
16. Sparano et al. Abstract GS1-05, SABCS 2022.
17. Sparano and Paik. J Clin Oncol. 2008.
Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, and Oncotype DX Colon Recurrence Score are registered trademarks, and "Making cancer care smarter" is a pending registered trademark of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation.